VANCOUVER, British Columbia, Feb. 28, 2011 /PRNewswire/ — Allon
Therapeutics Inc. (TSX: NPC), today announced that Gordon C.
McCauley, President and CEO, will present at
RetailInvestorConferences.com.DATE:
March 3rd, 2011TIME:
3:00 PM ESTLINK:
www.retailinvestorconferences.comThis
will be a live, interactive online event where investors are
invited to ask the company questions in real-time both in the
presentation hall as well as the company’s “virtual trade booth.”
If attendees are not able to join the event live in real-time, an
on-demand archive will be available for 90 days.
It is recommended that investors pre-register to save time and
receive event updates.
About Allon Therapeutics Inc.:Allon Therapeutics Inc. is a
clinical-stage biotechnology company focused on bringing to market
innovative central nervous system therapies. Allon’s lead drug
davunetide, is proceeding in a pivotal Phase 2/3 clinical trial in
an orphan indication, progressive supranuclear palsy (PSP), under
an SPA with the FDA. This pivotal trial is based upon statistically
significant human efficacy demonstrated in amnestic mild cognitive
impairment, cognitive impairment associated with schizophrenia, and
positive biomarker data. The Company is listed on the Toronto Stock
Exchange under the trading symbol “NPC” and based in
Vancouver.
For additional information please visit the company’s
website: www.allontherapeutics.com
About
RetailInvestorConferences.com:RetailInvestorConferences.com,
created by BetterInvesting
(NAIC), PR Newswire and MUNCmedia, is the first
monthly virtual investor conference series that provides an
interactive forum for presenting companies to meet directly
‘/>”/>
SOURCE